Business Description
Merck & Co Inc
NAICS : 325412
SIC : 2834
ISIN : US58933Y1055
Compare
Compare
Traded in other countries / regions
MRK.USAMRCK34.BrazilMRK.Argentina6MK.GermanyMRK.MexicoMRK.Peru1MRKX.ItalyMRK.Austria6MKd.UK6MK.BulgariaMRK.ChileMRK.FranceMRK.Ukraine IPO Date
2023-03-13Description
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.38 | |||||
| Equity-to-Asset | 0.38 | |||||
| Debt-to-Equity | 0.86 | |||||
| Debt-to-EBITDA | 1.98 | |||||
| Interest Coverage | 11.3 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.9 | |||||
| Beneish M-Score | -2.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 13 | |||||
| 3-Year EBITDA Growth Rate | -12.2 | |||||
| 3-Year EPS without NRI Growth Rate | -20.2 | |||||
| 3-Year FCF Growth Rate | 16.1 | |||||
| 3-Year Book Growth Rate | 14.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 83.01 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.75 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 84.24 | |||||
| 9-Day RSI | 65.15 | |||||
| 14-Day RSI | 52.23 | |||||
| 3-1 Month Momentum % | -9.07 | |||||
| 6-1 Month Momentum % | -18.3 | |||||
| 12-1 Month Momentum % | 0.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.36 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.49 | |||||
| Days Inventory | 151.53 | |||||
| Days Sales Outstanding | 63.71 | |||||
| Days Payable | 86.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.92 | |||||
| Dividend Payout Ratio | 0.52 | |||||
| 3-Year Dividend Growth Rate | 6.1 | |||||
| Forward Dividend Yield % | 3.16 | |||||
| 5-Year Yield-on-Cost % | 4.29 | |||||
| Shareholder Yield % | 2.37 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 75.82 | |||||
| Operating Margin % | 22.41 | |||||
| Net Margin % | 19.23 | |||||
| FCF Margin % | 23.38 | |||||
| ROE % | 29.3 | |||||
| ROA % | 11.06 | |||||
| ROIC % | 16.16 | |||||
| 3-Year ROIIC % | -81.32 | |||||
| ROC (Joel Greenblatt) % | 60.04 | |||||
| ROCE % | 17.83 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 21.17 | |||||
| Forward PE Ratio | 10.85 | |||||
| PE Ratio without NRI | 16.97 | |||||
| Shiller PE Ratio | 26.71 | |||||
| Price-to-Owner-Earnings | 25.78 | |||||
| PS Ratio | 4.06 | |||||
| PB Ratio | 5.75 | |||||
| Price-to-Tangible-Book | 44.2 | |||||
| Price-to-Free-Cash-Flow | 17.3 | |||||
| Price-to-Operating-Cash-Flow | 14.06 | |||||
| EV-to-EBIT | 18.47 | |||||
| EV-to-Forward-EBIT | 9.57 | |||||
| EV-to-EBITDA | 14.37 | |||||
| EV-to-Forward-EBITDA | 8.87 | |||||
| EV-to-Revenue | 4.38 | |||||
| EV-to-Forward-Revenue | 4.13 | |||||
| EV-to-FCF | 18.8 | |||||
| Price-to-GF-Value | 0.91 | |||||
| Price-to-Projected-FCF | 1.54 | |||||
| Price-to-Median-PS-Value | 0.92 | |||||
| Price-to-Graham-Number | 5.77 | |||||
| Earnings Yield (Greenblatt) % | 5.41 | |||||
| FCF Yield % | 5.87 | |||||
| Forward Rate of Return (Yacktman) % | 8.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck & Co Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 57,904.715 | ||
| EPS (TTM) (€) | 4.385 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 23.56 | ||
| 14-Day RSI | 52.23 | ||
| 14-Day ATR (€) | 0.2591 | ||
| 20-Day SMA (€) | 95.045 | ||
| 12-1 Month Momentum % | 0.51 | ||
| 52-Week Range (€) | 92.9 - 121.2 | ||
| Shares Outstanding (Mil) | 2,529.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merck & Co Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merck & Co Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Merck & Co Inc Frequently Asked Questions
What is Merck & Co Inc(CHIX:6MKd)'s stock price today?
The current price of CHIX:6MKd is €96.80. The 52 week high of CHIX:6MKd is €121.20 and 52 week low is €92.90.
When is next earnings date of Merck & Co Inc(CHIX:6MKd)?
The next earnings date of Merck & Co Inc(CHIX:6MKd) is 2025-02-04.
Does Merck & Co Inc(CHIX:6MKd) pay dividends? If so, how much?
The Dividend Yield %  of Merck & Co Inc(CHIX:6MKd) is 2.92% (As of Today), Highest Dividend Payout Ratio of Merck & Co Inc(CHIX:6MKd) was 1.96. The lowest was 0.37. And the median was 0.5. The  Forward Dividend Yield % of Merck & Co Inc(CHIX:6MKd) is 3.16%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers